Effect of a multitarget therapy with prednisolone, mycophenolate mofetil, and tacrolimus in a patient with type B insulin resistance syndrome complicated by lupus nephritis

Author:

Temmoku Jumpei1,Asano Tomoyuki1,Saito Kenji1,Matsumoto Haruki1,Fujita Yuya1,Furuya-Yashiro Makiko1,Matsuoka Naoki1,Oda Akira2,Tanabe Hayato3,Sato Shuzo1,Shio-Yano Kiori4,Sasajima Tomomi4,Kiko Yuichiro5,Kobayashi Hiroko1,Watanabe Hiroshi1,Shimabukuro Michio3,Migita Kiyoshi1

Affiliation:

1. Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan

2. Department of Nephrology and Hypertension, Fukushima Medical University School of Medicine, Fukushima, Japan

3. Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University School of Medicine, Fukushima, Japan

4. Department of Rheumatology, Fukushima Rosai Hospital, Iwaki, Fukushima, Japan

5. Department of Diagnostic Pathology, Fukushima Medical University School of Medicine, Fukushima, Japan

Abstract

ABSTRACT Type B insulin resistance syndrome (TBIR) is a rare autoimmune disease characterised by autoantibodies targeting insulin receptors. TBIR is often complicated by systemic lupus erythematosus (SLE). We describe the case of a 59-year-old Japanese man with TBIR complicated with lupus nephritis (LN), who presented with nephrotic syndrome and severe hypoglycaemia. Treatment with prednisolone (PSL), mycophenolate mofetil (MMF), and tacrolimus (TAC) resulted in improved SLE activity and glucose intolerance with the reduction of anti-insulin receptor autoantibodies. To the best of our knowledge, this is the first reported case of TBIR complicated with LN that was successfully treated using multitarget therapy with PSL, MMF, and TAC.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Prednisolone;Reactions Weekly;2022-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3